Performing CMC Activities with an NDA In Mind
As oligonucleotide therapeutics development continues to accelerate, there are necessary steps to execute and assure quality of oligonucleotide Active Pharmaceutical Ingredients (APIs) and Drug Products (DPs). The basis of this work begins with “good science” as well as a substantial understanding of the drug development process. Here are the major areas to consider. Clearly Delineate…
